コンテンツへスキップ
Merck
すべての画像(1)

Key Documents

View All Documentation

安全性情報

719897

Sigma-Aldrich

Resomer® RG 502H、ポリ(D,L-ラクチド-コ-グリコリド)

acid terminated, viscosity 0.16-0.24 dL/g 

別名:

PLGA

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

化学式:
[C3H4O2]x[C2H2O2]y
CAS番号:
26780-50-7
UNSPSCコード:
12162002
NACRES:
NA.23

品質水準

200

形状

amorphous

原料比

lactide:glycolide 50:50

劣化の時間枠

<3 months

粘度

0.16-0.24 dL/g

転移温度

Tg 42-46 °C

保管温度

2-8°C

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI Key

LCSKNASZPVZHEG-UHFFFAOYSA-N

アプリケーション

ポリ(D, L-ラクチド-co-グリコリド)（PLGA）は、以下の用途に使用されています：

  • 薬物の持続的放出を補助するためのH2Sドナーの非水系薬物送達システムの作製
  • PLGA–PEG–PLGAポリマーゲルに分散させたガンシクロビル充填ミクロスフェアを含むポリマーブレンドの調製。この製剤は、ガンシクロビルの持続的送達システムとして使用できます。
また、NO放出グルコースおよび乳酸センサーの作製にも使用できます。

法的情報

Evonik社の製品です。
RESOMER is a registered trademark of Evonik Rohm GmbH

関連製品

製品番号
詳細
価格

911593

NanoFabTx™ microfluidic - nano, device kit for synthesis of 100-200 nm nanoparticles and liposomes

911860

NanoFabTx™ microfluidic - micro, device kit for synthesis of 1-5 μm particles

911879

NanoFabTx™ microfluidic - micro, device kit for synthesis of 10-30 μm particles

909637

NanoFabTx™ PLGA-nano, for synthesis of 100 and 200 nm particles

912212

NanoFabTx™ PLGA-micro, for synthesis of 10-30 um particles

912220

NanoFabTx™ PLGA-micro, for synthesis of 1-5 μm particles

920436

NanoFabTx™ PEG-PLA drug formulation screening kit, for synthesis of PEGylated nanoparticles

915408

NanoFabTx™ PEGylated nanoparticle formulation screening kit

917796

NanoFabTx™ PEG-PLGA drug formulation screening kit, for synthesis of PEGylated nanoparticles

918881

NanoFabTx™ PEG-PCL drug formulation screening kit, for synthesis of PEGylated nanoparticles

918075

NanoFabTx™ PLA-nano, for synthesis of 100 and 200 nm particles

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

719897-1G:
719897-BULK:
719897-5G:
719897-VAR:

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number
BCCH1660
BCCG6651
BCCG1383
BCCF6039
BCCF0209

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Diazeniumdiolate-doped poly (lactic-co-glycolic acid)-based nitric oxide releasing films as antibiofilm coatings.
Cai W,et al.
Biomaterials, 33(32), 7933-7944 (2012)
A Patil et al.
AAPS PharmSciTech, 18(6), 2291-2302 (2017-01-20)
Hydrogen sulfide (H2S) targets both underlying factors in glaucoma pathogenesis by reducing elevated intraocular pressure (IOP) and providing retinal neuroprotection, whereas the current clinical approaches targets only reducing IOP. Therefore, H2S could be a potential superior candidate for glaucoma pharmacotherapy.
Z Zhuang et al.
Journal of dental research, 98(2), 200-208 (2018-11-06)
Periodontitis is characterized by the progressive destruction of tooth-supporting alveolar bone, which is mainly caused by chronic inflammation in response to persistent bacterial insult. It has recently become clear that the pathogenesis of periodontitis is associated with a high ratio
Rongcai Liang et al.
International journal of pharmaceutics, 454(1), 344-353 (2013-07-23)
Peptide or protein degradation often occurs when water flows into the dosage form. The aim of this study was to investigate the effect of water on exenatide acylation in poly(lactide-co-glycolide) (PLGA) microspheres. Exenatide-loaded PLGA microspheres were incubated at different relative
Shu-Chun Chuang et al.
Parasites & vectors, 6, 34-34 (2013-02-13)
Current development efforts of subunit vaccines against Toxoplasma gondii, the etiological agent of toxoplasmosis, have been focused mainly on tachyzoite surface antigen 1 (SAG1). Since microparticles made from poly (lactide-co-glycolide) (PLG) polymers have been developed as safe, potent adjuvants or
関連する文献をすべて表示

資料

Poly(Glycerol Sebacate) in Tissue Engineering and Regenerative Medicine

The world of commercial biomaterials has stagnated over the past 30 years as few materials have successfully transitioned from the bench to clinical use. Synthetic aliphatic polyesters have continued to dominate the field of resorbable biomaterials due to their long history and track record of approval with the U.S. Food and Drug Administration (FDA).

Biodegradable Polyester-based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

Biodegradable Polyester-based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

Biodegradable Polyester Based Nanoparticle Formation by Miniemulsion Technique

Aliphatic polyesters such as polylactide, poly(lactide-co-glycolide) and polycaprolactone, as well as their copolymers, represent a diverse family of synthetic biodegradable polymers that have been widely explored for medical uses and are commercially available.

すべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）